Pamidronic acid sodium

Cat. No.: HY-B0012B: FAQs
Data Sheet Handling Instructions Technical Support

Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.

For research use only. We do not sell to patients.

Pamidronic acid sodium Chemical Structure

CAS No. : 89131-02-2

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Pamidronic acid sodium:

Pamidronic acid Pamidronate disodium pentahydrate

Other Forms of Pamidronic acid sodium:

Pamidronic acid In-stock
Pamidronate disodium pentahydrate In-stock
Pamidronate disodium Get quote

1 Publications Citing Use of MCE Pamidronic acid sodium

•Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All Wnt Isoform Specific Products:

View All Isoforms

Wnt1 Wnt3 Wnt5 Wnt7

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Pamidronic acid sodium (0.001-1000 µM, 72 h) inhibits the cell viability of osteosarcoma cells POS, HMPOS and COS31, exhibits no cytotoxicity to fibroblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	POS, HMPOS and COS31
Concentration:	0.001-1000 µM
Incubation Time:	72 h
Result:	Inhibited the cell viability.

In Vivo

Pamidronic acid sodium (3 mg/kg, ear vein injection, once monthly for 14 weeks) improves the bone structure, alleviates the degenerative changes of cartilage, exhibits protective effect against osteoarthritis in rabbit models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Anterior cruciate ligament transection (ACLT)-induced osteoarthritis in rabbits^[3]
Dosage:	3 mg/kg
Administration:	ear vein injection, once monthly for 14 weeks
Result:	Increased bone volume fraction (BV/TV), trabecular thickness (TbTh) and trabecular number (TbN). Reduced the erosion of cartilage surface, increase the content of chondrocytes and matrix.

Molecular Weight

257.05

Formula

C₃H₁₀NNaO₇P₂

CAS No.

89131-02-2

SMILES

O=P(O)(O[Na])C(O)(CCN)P(O)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Ashton JA, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cellsfrom dogs. Am J Vet Res. 2005 May;66(5):885-91. [Content Brief]

[2]. Xu Y, et al. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Mar 22. [Content Brief]

[3]. Lv Y, et al. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits. BMC Musculoskelet Disord. 2014 Nov 6;15:370. [Content Brief]

[4]. Kovacs R, et al. The synthesis of pamidronic derivatives in different solvents: An optimization and a mechanistic study[J]. Heteroatom Chemistry, 2014, 25(3): 186-193.